WENA סך נכסי הפעילות העסקית anewmeds.com
Anew Medical, Inc. (WENA) is developing an advanced gene therapy system based on the Klotho protein to combat ALS and Alzheimer's disease, leveraging patent protection and biotech partnerships. The market dynamics of total assets, reaching 30.77 as reflected in the price action, are driven by the use of automated molecular analysis to accelerate research. As the startup is currently building its brand, investments in the company remain high-risk and speculative in nature.
פילוחים אנליטיים ודוחות נתונים של חברת Anew Medical, Inc. (WENA)
Optimizing the logistics of pharmaceutical substances for neurological drugs through a laboratory pool minimizes the operational risks of Anew Medical, Inc., while the level of consolidated assets, calculated reversely via ROA, reflects the total volume of resources formed through equity and debt, allowing the investor to identify hidden leverage behind the rising share price and objectively assess the stability of the business's asset base.